Tags

Type your tag names separated by a space and hit enter

Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
Vaccine. 2007 Mar 22; 25(13):2451-7.V

Abstract

The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Madhi SA
University of the Witwatersrand/Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, South Africa. madhis@hivas.com
Adrian P
No affiliation info available
Kuwanda L
No affiliation info available
Jassat W
No affiliation info available
Jones S
No affiliation info available
Little T
No affiliation info available
Soininen A
No affiliation info available
Cutland C
No affiliation info available
Klugman KP
No affiliation info available

MeSH

Antibody FormationChildChild, PreschoolDouble-Blind MethodFemaleHIVHIV InfectionsHumansImmunization, SecondaryInfantMalePneumococcal InfectionsPneumococcal VaccinesStreptococcus pneumoniaeTreatment OutcomeVaccines, Conjugate

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17023095

Citation

Madhi, Shabir A., et al. "Long-term Immunogenicity and Efficacy of a 9-valent Conjugate Pneumococcal Vaccine in Human Immunodeficient Virus Infected and Non-infected Children in the Absence of a Booster Dose of Vaccine." Vaccine, vol. 25, no. 13, 2007, pp. 2451-7.
Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine. 2007;25(13):2451-7.
Madhi, S. A., Adrian, P., Kuwanda, L., Jassat, W., Jones, S., Little, T., Soininen, A., Cutland, C., & Klugman, K. P. (2007). Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine, 25(13), 2451-7.
Madhi SA, et al. Long-term Immunogenicity and Efficacy of a 9-valent Conjugate Pneumococcal Vaccine in Human Immunodeficient Virus Infected and Non-infected Children in the Absence of a Booster Dose of Vaccine. Vaccine. 2007 Mar 22;25(13):2451-7. PubMed PMID: 17023095.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. AU - Madhi,Shabir A, AU - Adrian,Peter, AU - Kuwanda,Locadiah, AU - Jassat,Wasilla, AU - Jones,Stephanie, AU - Little,Tessa, AU - Soininen,Anu, AU - Cutland,Clare, AU - Klugman,Keith P, Y1 - 2006/09/20/ PY - 2006/10/7/pubmed PY - 2007/9/15/medline PY - 2006/10/7/entrez SP - 2451 EP - 7 JF - Vaccine JO - Vaccine VL - 25 IS - 13 N2 - The long-term immunogenicity and vaccine efficacy (VE) of a 9-valent conjugate pneumococcal vaccine was studied in HIV infected and HIV non-infected children. VE against vaccine-serotype invasive pneumococcal disease following 6.16 years of follow-up persisted in HIV non-infected children (77.8%; 95% CI 34.4-92.5 compared to 83% after 2.3 years of follow-up), and declined from 65% to 38.8% (95% CI -7.8 to 65.2) in HIV infected children. HIV non-infected vaccinees had equal (serotypes 4, 6B, 14, 19F) or greater (serotypes 9V, 18C, 23F) proportions of serotype-specific antibody concentrations of > or =0.2microg/ml to vaccine-serotypes analyzed compared to HIV infected vaccinees at 5.3 years of age. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/17023095/Long_term_immunogenicity_and_efficacy_of_a_9_valent_conjugate_pneumococcal_vaccine_in_human_immunodeficient_virus_infected_and_non_infected_children_in_the_absence_of_a_booster_dose_of_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(06)01021-8 DB - PRIME DP - Unbound Medicine ER -